文献速递神经肿瘤

生长激素分泌型垂体大腺瘤与非霍奇金淋巴瘤同时发生并对多柔比星治疗有反应:病例报告与文献综述

Growth hormone-secreting pituitary macroadenoma presenting concurrently with non-Hodgkin's lymphoma and responding to doxorubicin treatment: case report and review of the literature.
PubMed 文献 · Acta Neurochir (Wien) · 2018-10-29

本文报告一例以恶心、呕吐及肢端肥大症表现就诊的患者,检查诊断为垂体腺瘤及纵隔非霍奇金淋巴瘤。接受两个周期R-CHOP化疗后,影像显示鞍区肿瘤体积显著缩小。肿瘤切除后,冰冻及永久切片仅显示坏死物质。作者认为,多柔比星用于治疗复发或难治性垂体腺瘤的潜在价值可能需要进一步研究。

要点

  • 患者同时诊断生长激素分泌型垂体大腺瘤与纵隔非霍奇金淋巴瘤。
  • 两个周期R-CHOP化疗后影像显示鞍区肿瘤体积显著缩小。
  • 手术切除标本冰冻及永久切片仅见坏死物质。

核心结论

  • 作者认为,多柔比星用于复发或难治性垂体腺瘤的潜在价值可能需要进一步研究。

研究设计与样本

  • 病例报告并附文献综述。

主要发现

  • 患者因恶心、呕吐及肢端肥大症表现就诊,检查诊断为垂体腺瘤及纵隔非霍奇金淋巴瘤。
  • 接受两个周期R-CHOP化疗后,影像显示鞍区肿瘤体积显著缩小。
  • 肿瘤切除后,冰冻及永久切片仅显示坏死物质。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a case report of a patient who presented with nausea and vomiting, as well as acromegalic features. Following testing, a pituitary adenoma and mediastinal non-Hodgkin's lymphoma were diagnosed. Following two cycles of R-CHOP chemotherapy, imaging showed significant decrease in size of the sellar tumor. Following resection of tumor, both frozen and permanent section revealed only necrotic material. Further research into the potential utility of doxorubicin for the treatment of recurrent or refractory pituitary adenomas may be warranted.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Lekovic GP, Batra A, Barnard ZR, et al. Growth hormone-secreting pituitary macroadenoma presenting concurrently with non-Hodgkin's lymphoma and responding to doxorubicin treatment: case report and review of the literature. Acta Neurochir (Wien). 2018. PMID: 30370442. doi:10.1007/s00701-018-3714-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。